|Table of Contents|

Comparison of the diagnostic efficacy of 18F-PSMA-1007 PET/CT using different diagnostic criteria for prostate cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 15
Page:
2895-2899
Research Field:
Publishing date:

Info

Title:
Comparison of the diagnostic efficacy of 18F-PSMA-1007 PET/CT using different diagnostic criteria for prostate cancer
Author(s):
CHEN Dandan; LOU Yunlong; SONG Li
Department of Nuclear Medicine,Meizhou People's Hospital,Guangdong Meizhou 514013,China.
Keywords:
prostate tumor; miPSMA score; semi-quantitative analysis; PSMA-RADS score; positron emission tomography; X-ray computed tomography; diagnosis
PACS:
R737.25
DOI:
10.3969/j.issn.1672-4992.2023.15.024
Abstract:
Objective:To explore the differential value of 18F-PSMA-1007 PET/CT diagnostic criteria in benign and malignant prostate lesions,and to compare the difference in diagnostic efficacy.Methods:Retrospective analysis was performed on 102 cases of prostate cancer with high clinical suspicion and 18F-PSMA-1007 PET/CT images and clinical data.miPSMA score,semi-quantitative analysis and PSMA-RADS score were used for blind diagnosis of prostate cancer,and pathological results were used as the gold standard.The diagnostic efficacy of prostate cancer foci was obtained,and area under ROC curve (AUC) was compared by MedCalc software.Results:In the 102 patients,there were 57 cases of prostate acinar carcinoma,the other 45 cases of benign lesions,including 1 case of prostatic abscess,3 cases of prostatic hyperplasia with inflammation,38 cases of prostatic hyperplasia changes and 3 cases of benign prostatic tissue.The sensitivity and specificity of miPSMA score,semi-quantitative analysis and PSMA-RADS score for diagnosis of prostate cancer lesions were 70.2%(40/57) and 88.9%(40/45),73.7%(42/57) and 95.6%(43/45),78.9%(45/57) and 46.7%(21/45),the three diagnostic criteria had statistical significance in the differentiation of benign and malignant prostate lesions (P＜0.001).But there was no significant difference in the AUC of the three diagnostic criteria (all P values>0.05).Conclusion:miPSMA score,semi-quantitative analysis and PSMA-RADS score are of certain value in the differential diagnosis of benign and malignant prostate lesions,but there is no significant difference in the diagnostic efficacy of prostate cancer.The sensitivity of the three criteria is high,but the specificity of PSMA-RADS score is poor.

References:

［1］ SIEGEL RL,MIILLER KD,FUCHS HE,et al.Cancer statistics,2021［J］.CA Cancer J Clin,2021,71（1）:7-32.
［2］ GROZESCUT P.Prostate cancer between prognosis and adequate proper therapy ［J］.J Med Life,2017，10:5-12.
［3］ CARDINALE J,SCHAFER M,BENESOVA M,et al.Preclinical evaluation of 18F-PSMA-1007 PET/CT,a new prostate-specific membrane antigen ligand for prostate cancer imaging ［J］.J Nucl Med,2017,58(3):425-431．
［4］ EIBER M,HERRMANN K,CALAIS J,et al.Prostate cancer molecular imaging standardized evaluation (PROMISE):Proposed miTNM classification for the interpretation of PSMA-ligand PET/CT［J］.J Nucl Med，2018,59:469-478.
［5］马乐，张万春，瞿洛萍，等.18F-DCFPyL PET/CT的不同诊断标准对前列腺癌原发病灶的诊断价值［J］.中华核医学与分子影像杂志，2022,42（12）:734-738. MA L,ZHANG WC,ZHAI LP,et al.Diagnostic values of different diagnostic criteria of 18F-DCFPyL PET/CT for primary prostate cancer［J］.Chin J Nucl Med Mol Imaging,2022,42（12）:734-738.
［6］ROWE SP,PIENTA KJ,POMPER MG,et al.PSMA-RADS vesion 1.0:a step towords standardizing the interpreration and reporting of PSMA-targeted PET imaging studies［J］.Eur Urol,2018,73(4):485-487.
［7］ 李曾，廖洪，毛顿，等.18F-PSMA-1007 PET/CT在初诊PCa精准评估中的价值及对临床治疗决策的影响［J］.中国癌症杂志，2020，30（3）:231-236. LI Z,LIAO H,MAO D,et al.The value of 18F-PSMA-1007 PET/CT in accurate assessment of initial PCa and its impact on clinical treatment decision［J］.Chinese Journal of Cancer,2020，30（3）:231-236.
［8］ 邹世娟，宋双，陈利星，等.68Ga-PSMA-11PET/CT 与MRI对中高危PCa诊断和分期的对比［J］.中华核医学与分子影像杂志，2020，40（12）：710-714. ZOU SJ,SONG S,CHEN LX,et al.Comparison of 68Ga-PSMA-11PET/CT and MRI in the diagnosis and staging of high risk PCa ［J］.Chinese Journal of Nuclear Medicine and Molecular Imaging,2020,40(12):710-714.
［9］ 蒋翠萍,臧士明,徐磊,等.68Ga-PSMA-11PET/CT 对未经治疗PCa的临床决策的影响［J］.临床泌尿外科杂志,2018,33(7):551-555. JIANG CP,ZANG SM,XU L,et al.Effects of 68Ga-PSMA-11PET/CT on clinical decision making in untreated PCa［J］.Journal of Clinical Urology,2018,33(7):551-555.
［10］LOPCI E,SAITA A,LAZZERI M,et al.68Ga-PSMA positron emission tomography/computerized tomography for primary diagnosis of prostate cancer in men with contraindicationgs to or negative multiparametric magnetic resonance imaging:a prospective observational stdudy［J］.J Urol,2018,200(1):95-103.
［11］ 秦露平，吕杰，李名钊，等.68Ga-PSMA-11半定量指标对前列腺良恶性病变鉴别诊断的价值［J］.中华核医学与分子影像杂志，2019，39（2）：67-71. QIN LP,LYU J,LI MZ,et al.The value of 68Ga-PSMA-11 semi-quantitative index in the differential diagnosis of benign and malignant prostate lesions ［J］.Chinese Journal of Nuclear Medicine and Molecular Imaging,2019,39(2):67-71.
［12］ 王卓楠，吴开杰，郑安琪,等.18F-PSMA-1007 PET/CT在PCa诊断与预后预测中的价值初探［J］.现代泌尿外科杂志，2021，26（4）：305-308. WANG ZN,WU KJ,ZHENG AQ,et al.The value of 18F-PSMA-1007 PET/CT in the diagnosis and prognosis of PCa［J］.Journal of Modern Urology,2021,26(4):305-308.
［13］ 刘大亮，李国权，陈玲，等.68Ga-PSMA-617 PET/CT与多参数MRI诊断PCa的对比研究［J］.中华核医学与分子影像杂志，2019，39（2）：72-76. LIU DL,LI GQ,CHEN L,et al.Comparison of PCa diagnosis with 68Ga-PSMA-617 PET/CT and multi-parameter MRI［J］.Chinese Journal of Nuclear Medicine and Molecular Imaging,2019,39(2):72-76.
［14］楼云龙，陈丹丹，陈南辉，等.18F-PSMA-1007 PET/CT 在PCa术前诊断中的价值［J］.现代泌尿生殖肿瘤杂志，2022,14（5）:313-315. LOU YL,CHEN DD,CHEN NH，et al.Value of 18F-PSMA-1007 PET/CT in preoperative diagnosis of prostate cancer［J］.J Contemp Urol Reprod Oncol,2022,14（5）:313-315.
［15］ 刘亚超，程诺，李云钢，等.18F-PSMA-1007 PET/CT显像应用miPSMA评分诊断PCa的价值［J］.中国医学影像学杂志，2021,29(1)：47-55. LIU YC,CHENG N,LI YG,et al.The value of 18F-PSMA-1007 PET/CT imaging in the diagnosis of PCa with miPSMA score ［J］.Chinese Journal of Medical Imaging，2021,29(1):47-55.

Memo

Memo:
广东省梅州市人民医院培育项目（编号：PY-C2020018）
Last Update: 2023-06-30